GRPH Key Statistics, Chart & Performance
The current stock price of GRPH is 3.18 USD. In the past month the price increased by 4.95%. In the past year, price increased by 29.8%.
GRPH Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to GRPH. When comparing the yearly performance of all stocks, GRPH is one of the better performing stocks in the market, outperforming 88.02% of all stocks.
GRPH Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GRPH. While GRPH has a great health rating, there are worries on its profitability.
GRPH Financial Highlights
Over the last trailing twelve months GRPH reported a non-GAAP Earnings per Share(EPS) of -2.19. The EPS decreased by -18.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -66.14% | ||
| ROE | -67.9% | ||
| Debt/Equity | 0 |
GRPH Forecast & Estimates
6 analysts have analysed GRPH and the average price target is 7.14 USD. This implies a price increase of 124.53% is expected in the next year compared to the current price of 3.18.
For the next year, analysts expect an EPS growth of 81.37% and a revenue growth -100% for GRPH
GRPH Ownership
GRPH Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.39 | 394.886B | ||
| AMGN | AMGEN INC | 17.06 | 206.949B | ||
| GILD | GILEAD SCIENCES INC | 17.1 | 189.204B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.44 | 121.258B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.91 | 82.557B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.99 | 43.353B | ||
| INSM | INSMED INC | N/A | 31.961B | ||
| BIIB | BIOGEN INC | 13.22 | 29.513B | ||
| NTRA | NATERA INC | N/A | 28.022B | ||
| INCY | INCYTE CORP | 13.54 | 21.279B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GRPH
Company Profile
Graphite Bio, Inc. operates as a clinical-stage gene editing company. The company is headquartered in South San Francisco, California and currently employs 120 full-time employees. The company went IPO on 2021-06-25. The firm has a gene editing platform that is designed to correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its research program, GPH102 for the treatment of beta-thalassemia, leverages its gene replacement platform technology by replacing one or both copies of the mutated beta-globin (HBB) gene through HDR to restore HgbA expression to levels. GPH201 is an investigational treatment for X-linked severe combined immunodeficiency syndrome (XSCID), a rare, life-threatening disease where multiple mutations in a single gene (IL2RG) prevent normal immune system function. GPH301 is for the treatment of Gaucher disease. Its pipeline program also includes therapeutic protein production and non-genotoxic conditioning (NGTC).
Company Info
GRAPHITE BIO INC
611 Gateway Blvd, Suite 120
South San Francisco CALIFORNIA US
CEO: Josh Lehrer
Employees: 120
Phone: 16504840886
GRAPHITE BIO INC / GRPH FAQ
Can you describe the business of GRAPHITE BIO INC?
Graphite Bio, Inc. operates as a clinical-stage gene editing company. The company is headquartered in South San Francisco, California and currently employs 120 full-time employees. The company went IPO on 2021-06-25. The firm has a gene editing platform that is designed to correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its research program, GPH102 for the treatment of beta-thalassemia, leverages its gene replacement platform technology by replacing one or both copies of the mutated beta-globin (HBB) gene through HDR to restore HgbA expression to levels. GPH201 is an investigational treatment for X-linked severe combined immunodeficiency syndrome (XSCID), a rare, life-threatening disease where multiple mutations in a single gene (IL2RG) prevent normal immune system function. GPH301 is for the treatment of Gaucher disease. Its pipeline program also includes therapeutic protein production and non-genotoxic conditioning (NGTC).
Can you provide the latest stock price for GRAPHITE BIO INC?
The current stock price of GRPH is 3.18 USD. The price decreased by -2.75% in the last trading session.
What is the dividend status of GRAPHITE BIO INC?
GRPH does not pay a dividend.
What is the ChartMill technical and fundamental rating of GRPH stock?
GRPH has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What sector and industry does GRAPHITE BIO INC belong to?
GRAPHITE BIO INC (GRPH) operates in the Health Care sector and the Biotechnology industry.